Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 75, Issue 6, pp 1317–1320 | Cite as

Targeting the EWS–FLI1 transcription factor in Ewing sarcoma

  • R. Tancredi
  • A. Zambelli
  • G. A. DaPrada
  • V. Fregoni
  • L. Pavesi
  • A. Riccardi
  • S. Burdach
  • P. J. Grohar
  • M. D’Incalci
Short Communication

Abstract

Purpose

Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS–FLI1. This combination was evaluated in Ewing sarcoma patient who was progressing with standard therapies.

Methods

Trabectedin was given as a 24-h iv infusion on day 1 at the dose of 1 mg/sqm, and irinotecan 75 mg/sqm on day 2 and then on days 2 and 4, every 3 weeks from the seventh course.

Results

The therapy was well tolerated with transient hematological toxicity and transaminitis and induced stabilization of the disease lasting for 11 courses, with clinical improvement and marked reduction of the need for opioids. However, shortly before the 12th course, sudden death occurred, possibly due to cerebral stroke, presumably not related to the drug treatment.

Conclusions

The encouraging clinical benefit observed with the combination and its good tolerability deserves further investigation in Ewing sarcoma.

Keywords

Ewing sarcoma Trabectedin Irinotecan Combination therapy Transcription mechanism Werner gene EWS–FLI1 

Notes

Conflict of interest

The authors declare that they have no conflict of interest, except M. D. who has received honoraria from Pharma Mar for Scientific Boards.

References

  1. 1.
    Moore DD, Haydon RC (2014) Ewing’s sarcoma of bone. Cancer Treat Res 162:93–115. doi: 10.1007/978-3-319-07323-1_5 PubMedGoogle Scholar
  2. 2.
    (2014) Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3:iii113–iii123. doi: 10.1093/annonc/mdu256
  3. 3.
    Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G et al (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359(6391):162–165. doi: 10.1038/359162a0 CrossRefPubMedGoogle Scholar
  4. 4.
    Maksimenko A, Malvy C (2005) Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin Ther Targets 9(4):825–830. doi: 10.1517/14728222.9.4.825 CrossRefPubMedGoogle Scholar
  5. 5.
    Kovar H (2014) Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Expert Opin Ther Targets 18(11):1315–1328. doi: 10.1517/14728222.2014.947963 CrossRefPubMedGoogle Scholar
  6. 6.
    Cuevas C, Francesch A (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 26(3):322–337. doi: 10.1039/b808331m CrossRefPubMedGoogle Scholar
  7. 7.
    D’Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9(8):2157–2163. doi: 10.1158/1535-7163.MCT-10-0263 CrossRefPubMedGoogle Scholar
  8. 8.
    D’Incalci M, Badri N, Galmarini CM, Allavena P (2014) Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 111(4):646–650. doi: 10.1038/bjc.2014.149 CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D’Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37(1):97–105. doi: 10.1016/S0959-8049(00)00357-9 CrossRefPubMedGoogle Scholar
  10. 10.
    Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7(8):961–966. doi: 10.1038/91008 CrossRefPubMedGoogle Scholar
  11. 11.
    Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK (2007) Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 104(32):13062–13067. doi: 10.1073/pnas.0609877104 CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D’Incalci M, Damia G (2008) Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44(4):609–618. doi: 10.1016/j.ejca.2008.01.003 CrossRefPubMedGoogle Scholar
  13. 13.
    Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D’Incalci M (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65(7):2964–2971. doi: 10.1158/0008-5472.CAN-04-4037 CrossRefPubMedGoogle Scholar
  14. 14.
    Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D’Incalci M, Allavena P (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23(2):249–262. doi: 10.1016/j.ccr.2013.01.008 CrossRefPubMedGoogle Scholar
  15. 15.
    Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D’Incalci M, Taraboletti G (2014; E-pub) Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer. doi: 10.1002/ijc.29023
  16. 16.
    Minuzzo M, Marchini S, Broggini M, Faircloth G, D’Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97(12):6780–6784. doi: 10.1073/pnas.97.12.6780 CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 97(12):6775–6779CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D’Incalci M, Pilotti S, Mantovani R (2009) Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8(2):449–457. doi: 10.1158/1535-7163.MCT-08-0848 CrossRefPubMedGoogle Scholar
  19. 19.
    Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D’Incalci M (2014) Mode of action of trabectedin in myxoid liposarcomas. Oncogene 33(44):5201–5210. doi: 10.1038/onc.2013.462 CrossRefPubMedGoogle Scholar
  20. 20.
    Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ (2011) Ecteinascidin 743 interferes with the activity of EWS–FLI1 in Ewing sarcoma cells. Neoplasia 13(2):145–153CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Grohar PJ, Segars LE, Yeung C, Pommier Y, D’Incalci M, Mendoza A, Helman LJ (2014) Dual targeting of EWS–FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res 20(5):1190–1203. doi: 10.1158/1078-0432.CCR-13-0901 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • R. Tancredi
    • 1
  • A. Zambelli
    • 2
  • G. A. DaPrada
    • 1
  • V. Fregoni
    • 1
  • L. Pavesi
    • 1
  • A. Riccardi
    • 3
  • S. Burdach
    • 4
  • P. J. Grohar
    • 5
  • M. D’Incalci
    • 6
  1. 1.Medical Oncology UnitI.R.C.C.S. Salvatore Maugeri FoundationPaviaItaly
  2. 2.Medical Oncology Unit, Azienda Ospedaliera Giovanni XXIIIPiazza OMS - Organizzazione Mondiale della Sanità, 1BergamoItaly
  3. 3.Medical Oncology Unit, Department of Internal MedicineUniversity of PaviaPaviaItaly
  4. 4.Department of Pediatrics and Children’s Cancer Research Center (CCRC)Technische Universität München (TUM)MunichGermany
  5. 5.Monroe Carrell Jr. Children’s Hospital and the Vanderbilt Ingram Cancer CenterNashvilleUSA
  6. 6.Laboratory of Cancer Pharmacology, Department of OncologyIRCCS-Istituto di Ricerche Farmacologiche Mario NegriMilanItaly

Personalised recommendations